Iguana Healthcare Management buys $16,348,000 stake in Ultragenyx Pharmaceutical Inc (RARE)

Ultragenyx Pharmaceutical Inc (RARE) : Iguana Healthcare Management scooped up 60,000 additional shares in Ultragenyx Pharmaceutical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 200,000 shares of Ultragenyx Pharmaceutical Inc which is valued at $16,348,000.Ultragenyx Pharmaceutical Inc makes up approximately 7.51% of Iguana Healthcare Management’s portfolio.

Other Hedge Funds, Including , Clearbridge Investments reduced its stake in RARE by selling 2 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 2,730 shares of RARE which is valued at $223,150.Tower Research Capital (trc) reduced its stake in RARE by selling 304 shares or 53.05% in the most recent quarter. The Hedge Fund company now holds 269 shares of RARE which is valued at $15,747.Gilder Gagnon Howe Co reduced its stake in RARE by selling 2 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 6,840 shares of RARE which is valued at $396,994. Ultragenyx Pharmaceutical Inc makes up approx 0.01% of Gilder Gagnon Howe Co’s portfolio.American Century Companies Inc boosted its stake in RARE in the latest quarter, The investment management firm added 693 additional shares and now holds a total of 42,259 shares of Ultragenyx Pharmaceutical Inc which is valued at $2,452,712.Strs Ohio reduced its stake in RARE by selling 2,500 shares or 39.68% in the most recent quarter. The Hedge Fund company now holds 3,800 shares of RARE which is valued at $237,956.

Ultragenyx Pharmaceutical Inc opened for trading at $81.18 and hit $83 on the upside on Monday, eventually ending the session at $82.72, with a gain of 1.60% or 1.3 points. The heightened volatility saw the trading volume jump to 4,69,384 shares. Company has a market cap of $3,380 M.

On the company’s financial health, Ultragenyx Pharmaceutical Inc reported $-1.64 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Nov 7, 2016. Analyst had a consensus of $-1.56.Analysts expectations of $ .03.During the same quarter in the previous year, the company posted $-1.03 EPS.

Many Wall Street Analysts have commented on Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc was Downgraded by Citigroup to ” Sell” on Nov 14, 2016.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Ultragenyx Pharmaceutical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ultragenyx Pharmaceutical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.